secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001323885-21-000041
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q2 revenue $71.4M (+74.8% YoY); aMAZE trial fails efficacy endpoint
----------------------------------------------------------------------------

- Revenue $71.4M, up 74.8% YoY (73.5% constant currency); U.S. $60.1M (+78.4%), international $11.3M (+57.9%).
- Net loss per share $0.36; adjusted loss per share $0.30; adjusted EBITDA loss $2.7M.
- FY2021 revenue guidance raised to $270-275M (growth ~31-33%); adjusted loss per share guidance ~$1.20.
- aMAZE trial failed primary efficacy endpoint; safety endpoint met. Potential material adjustments expected in H2 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388521000041/0001323885-21-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388521000041/atrc-20210804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001323885-21-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer